我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

不同剂量阿托伐他汀对冠心病患者血脂 及血清高敏C反应蛋白的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第6期
页码:
716-719
栏目:
临床研究
出版日期:
2008-12-25

文章信息/Info

Title:
Effect of different doses of atorvastatin on serum lipid and inflammatory factor hsCRP in patients with coronary artery disease
作者:
桑震池; 陈书艳; 李月华; 王长谦; 李毅刚
上海交通大学医学院附属新华医院心内科,上海 200092
Author(s):
SANG Zhenchi;  CHEN Shuyan;  LI Yuehua;  WANG Changqian;  LI Yigang
Department of Cardiology, Xinhua Hospital, Shanghai 200092, China
关键词:
阿托伐他汀; 血脂; 高敏C反应蛋白
Keywords:
atorvastatin;  blood lipid;  highsensitive Creactive protein
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 观察不同剂量阿托伐他汀在冠心病中国患病人群中降低血脂幅度、降低高敏C反应蛋白（hs-CRP）之间的差别，以及hsCRP与血脂降低幅度之间的关联。方法 连续入选128例冠心病患者，随机分为2组，一组服用阿托伐他汀10 mg/d，另一组服用阿托伐他汀20 mg/d，分别在入院24 h内和服药后1月测定患者血脂、 hs-CRP，比较两组和不同亚组患者不同剂量血脂、hs-CRP的变化。结果 两组冠心病患者治疗1月后血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白B（ApoB）、hs-CRP显著下降（均P<0.01），hs-CRP变化值与血脂变化值无相关性，阿托伐他汀10 mg/d组和20 mg/d组相比，1月后血脂、hsCRP变化值无统计学差异。结论 冠心病患者无论是使用阿托伐他汀10 mg/d还是20 mg/d治疗1月,都能使血脂水平，包括TC、LDL-C、ApoB和炎症指标hs-CRP显著下降，同时阿托伐他汀的抗炎作用与降脂作用本身无相关性，但两剂量间并没有显著差异。
Abstract:
AIM To investigate the effects of different doses of atorvastatin on serum levels of the blood lipid and highsensitive Creactive protein (hsCRP) in Chinese patients with coronary artery disease and to study the relationship between hsCRP and blood lipid. METHODS One hundred and twentyeight consecutive patients with coronary artery disease were randomly divided into two groups. Patients in group A were given oral atorvastatin 10 mg once daily and patients in group B were given oral atorvastatin 20 mg once daily. The serum levels of blood lipid and hsCRP were measured with biochemistry assay 24 hours after admission and 1 month after therapy. The difference in blood lipid and hsCRP was compared between the two groups and subset groups. RESULTS The serum levels of total cholesterol, lower density lipoprotein cholesterol (LDLC), ApoB and hsCRP in the patients of the two groups after taking atorvastatin for a month were significantly lower than those before therapy (P<0.01). The changes of blood lipid and hsCRP were not significantly different between the two groups. CONCLUSION No significant therapeutic difference has been found in atorvastatin at doses of 10 mg/d or 20 mg/d. After onemonth therapy with atorvastatin of 10 mg/d or 20 mg/d, the serum levers of blood lipid, including total cholesterol, LDLC, ApoB and hsCRP are significantly decreased compared with those before therapy in patients of coronary artery disease. The antiinflammatory effect of atorvastatin is not related to lipid lowering.

参考文献/References

［1］ Kaplan IV, Levinson SS. Apolipoprotein and related testing as markets for coronary artery disease［J］. Lab Medica International, 1998, 15(1):12-14.

［2］ Almagor M, Keren A, Banai S. Increased Creactive protein level after coronary stent implantation in patients with stable coronary artery disease［J］. Am Heart J, 2003, 145(2):248-253.

［3］Ridker PM, Hennekens CH, Buring JE, et al. Creactive protein and other markets of inflammation in the prediction of cardiovascular disease in women［J］. N Engl J Med, 2000, 342(12):836-843.

［4］ Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation ,pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators［J］. Circulation, 1998, 98(9):839-844.

［5］ Haverkate F,Thomp son SG, Pyke SD, et al. Production of Creactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Anginal Pectoris Study Group［J］. Lancet, 1997, 349(9050):462-466.

［6］ Taniguchi H, Momiyama Y, Ohmori R, et al. Associations of plasma Creactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease［J］. Atherosclerosis, 2005, 178(1):173-177.

［7］ Ridker PM, Cannon CP, Morrow D, et al. Creactive protein levels and outcomes after statin therapy［J］. N Engl J Med, 2005, 352(1):20-28.

［8］ Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial［J］. JAMA, 2004, 291(9):1071-1080.

［9］ Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)［J］. JAMA, 2001, 285(19):2486-2497.

备注/Memo

备注/Memo:
收稿日期：2007-08-13.通讯作者：陈书艳，主任医师，主要从事调脂治疗在冠心病中的作用的研究Email:shuyan chen cn@yahoo.com.cn 作者简介：桑震池，硕士生Email:sangzc@163.com
更新日期/Last Update: 2009-03-24